SL43 is an orally active and potent SOS1 inhibitor with a Kd of 0.16 µM. SL43 disrupts SOS1-KRAS interaction, inhibits SOS1-mediated nucleotide exchange on KRAS mutants, and suppresses RAS-MAPK signaling. SL43 exerts antiproliferative activity against KRAS-mutant cancer cells, induces early apoptosis and G1 phase cell cycle arrest, and reduces phosphorylated MEK and ERK levels. SL43 suppresses tumor growth in a colorectal cancer xenograft model[1].
Molekulargewicht:
449.03
Formel:
C27H33ClN4
Target-Kategorie:
Apoptosis,ERK,MEK,p38 MAPK,Ras,SOS1
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
